Pathophysiology of oxidative stress in diabetes mellitus

Journal of Diabetes and its Complications

Volumn 15, Issue 4, 2001, Pages 203-210

  Lipinski, Boguslaw ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Diabetes; Fibrinogen; Oxidative stress

Indexed keywords

ANTIOXIDANT; FIBRINOGEN; LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN;

ANIMAL; ARTERIOSCLEROSIS; BLOOD; DIABETES MELLITUS; DIABETIC ANGIOPATHY; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW;

ANIMALS; ANTIOXIDANTS; ARTERIOSCLEROSIS; DIABETES COMPLICATIONS; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FIBRINOGEN; HUMANS; LIPOPROTEINS, LDL; OXIDATIVE STRESS;

EID: 0035407264     PISSN: 10568727     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1056-8727(01)00143-X     Document Type: Article

References (115)

1. Altshuler, C. H., & Angevine, D. M. (1949). Histochemical studies on the pathogenesis of fibrinoid. American Journal of Pathology, 25, 1061-1077.
2. Astrup, T. (1956). Biological significance of fibrinolysis. The Lancet, 2, 565-568.
3. Bagglioni, M. (1998). Chemokines and leukocyte traffic. Nature, 392, 565-569.
4. Baynes, J. W. (1991). Role of oxidative stress in development of complications in diabetes. Diabetes, 40, 405-412.
5. Belisario, M. A., Di Domenico, C., Pelagalli, A., Della Morte, R., & Staiano, N. (1997). Metal-ion catalyzed oxidation affects fibrinogen activity on platelet aggregation and adhesion. Biochimie, 79, 449-455.
6. Berlett, B. S., & Stadtman, E. R. (1997). Protein oxidation in aging, disease, and oxidative stress. Journal of Biological Chemistry, 272, 20313-20316.
7. Berliner, J. A., Territo, M. C., Sevanian, A., Ramin, S., Kim, J. A., Bamshad, B., Esterson, M., & Fogelman, A. M. (1990). Minimally modified low density lipoprotein stimulates monocyte endothelial interactions. Journal of Clinical Investigation, 85, 1260-1266.
8. Biewenga, G. P., Haenen, G. R., & Bast, A. (1997). The pharmacology of the antioxidant lipoic acid. General Pharmacology, 29, 315-331.
9. Borcea, V., Nourooz-Zadeh, J., Wolf, S. P., Klevesath, M., Hofmann, N., Urich, H., Wahl, P., Ziegler, R., Tritschler, H., Halliwell, B., & Nawroth, P. P. (1999). Alpha-lipoic acid decreases oxidative stress even in diabetic patients with poor glycemic control and albuminuria. Free Radical Biology & Medicine, 26, 1495-1500.
10. Cantero, M., Parra, T., & Conejo, J. R. (1998). Increased hydrogen peroxide formation in polymorphonuclear leukocytes of IDDM patients. Diabetes Care, 21, 326-327.
11. Capeillere-Blandin, C., Delaveau, T., & Descamps-Latscha, B. (1991). Structural modifications of human beta microglobulin treated with oxygen-derived radicals. Biochemical Journal, 277, 175-182.
12. Ceriello, A. (1993). Coagulation activation in diabetes mellitus: the role hyperglycaemia and therapeutic prospects. Diabetologia, 36, 1119-1125.
13. Ceriello, A. (1997). Fibrinogen and diabetes mellitus: is it time for intervention trials? Diabeteologia, 40, 731-734.
14. Ceriello, A. (1999). Hyperglycaemia: the bridge between non-enzymatic glycation and oxidative stress in the pathogenesis of diabetic complications. Diabetes, Nutrition & Metabolism, 12, 42-46.
15. Chowienczyk, P. J., Brett, S. E., Gopaul, N. K., Meeking, D., Marchetti, M., Russell-Jones, D. L., & Anggard, E. E. (2000). Oral treatment with an antioxidant (raxofelast) reduces oxidative stress and improves endothelial function in men with type 2 diabetes. Diabetologia, 43, 974-977.
16. Collier, A., Rumley, A., Rumley, A. G., Paterson, J. R., Leach, J. P., Lowe, G. D. O., & Small, M. (1992). Free radical activity and hemostatic fatcors in NIDDM patients with and without microalbuminuria. Diabetes, 41, 909-913.
17. Colwell, J. A. (1999). Inflammation and diabetic vascular complications. Diabetes Care, 22, 1927-1928.
18. Cook, N. S., & Ubben, D. (1990). Fibrinogen as a major risk factor in cardiovascular disease. Trends in Pharmacological Sciences, 11, 444-451.
19. Cristol, J.-P., Vela, C., Maggi, M.-F., Descomps, B., & Mourad, G. (1998). Oxidative stress and lipid abnormalities in renal transplant recipients with or without chronic rejection. Transplantation, 65, 1322-1328.
20. Cunningham, M. A., Rondeau, E., Chen, X., Coughlin, S. R., Holdsworth, S. R., & Tipping, P. G. (2000). Protease-activated receptor 1 mediates thrombin-dependent, cell-mediated renal inflammation in crescentic glomerulonephritis. Journal of Experimental Medicine, 191, 455-461.
21. Danesh, J., Collins, R., Appleby, P., & Peto, R. (1998). Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease. Meta-analyses of prospective studies. JAMA, the Journal of the American Medical Association, 279, 1477-1482.
22. Davie, S. J., Gould, B. J., & Yudkin, J. S. (1992). Effect of vitamin C on glycosylation of proteins. Diabetes, 41, 167-173.
23. Davies, K. J. A. (1987). Protein damage and degradation by oxygen radicals: I. General aspects. Journal of Biological Chemistry, 262, 9895-9905.
24. Davies, K. J. A., Lin, S. W., & Pacifici, R. E. (1987). Protein damage and degradation by oxygen radicals: IV. Degradation of denatured protein. Journal of Biological Chemistry, 262, 9914-9920.
25. de Lorgeril, M., Richard, M. J., & Arnaud, J. (1993). Lipid peroxides and antioxidant defenses in accelerated transplantation-associated coronary arteriosclerosis. American Heart Journal, 125, 974-978.
26. Deneke, S. M. (2000). Thiol-based antioxidants. Current Topics in Cell Regulation, 36, 151-180.
27. Devaraj, S., & Jialal, I. (2000). Oxidative stress and antioxidants in Type 2 diabetes. In: Bendich A., & Deckelbaum R. J. (Eds.), Primary and secondary preventive nutrition (pp. 117-125). Totowa, NJ: Humana Press (December).
28. Duguid, J. B. (1946). Thrombosis as a factor in the pathogenesis of coronary atherosclerosis. Journal of Pathology and Bacteriology, 58, 207-212.
29. Esterbauer, H., Gebicki, J., Puhl, H., & Jurgens, G. (1992). The role of lipid peroxidation and antioxidants in oxidative modification of LDL. Free Radical Biology & Medicine, 13, 341-346.
30. Ford, E. S. (1999). Body mass index, diabetes, and C-reative protein among US adults. Diabetes Care, 22, 1971-1977.
31. Frei, B., Stocker, R., & Ames, B. N. (1988). Antioxidant defenses and lipid peroxidation in human blood plasma. Proceedings of the National Academy of Sciences of the United States of America, 85, 9748-9752.
32. Fuller, C. J., Chandalia, M., Garg, A., Grundy, S. M., & Jialal, I. (1996). RRR-alpha-tocopherol acetate supplementation at pharmacologic doses decreases LDL oxidative susceptibility but not protein glycation in patients with DM. American Journal of Clinical Nutrition, 63, 753-759.
33. Galli, F., Canestrari, F., & Buonchristiani, U. (1999). Biological effects of oxidant stress in hemodialysis: the possible role of vitamin E. Blood Purification, 17, 79-94.
34. Ganda, O. P., & Arkin, C. F. (1992). Hyperfibrinogenemia: an important risk factor for vascular complication in diabetes. Diabetes Care, 15, 1245-1250.
35. Ghanem, H., van den Dorpel, M. A., Weimar, W., Man Veld, A. J., El-Kannishy, M. H., & Jansen, H. (1996). Increased LDL oxidation in stable kidney transplant recipients. Kidney International, 49, 488-493.
36. Grau, A. J., Buggle, F., Becher, H., Werle, E., & Hacke, W. (1996). The association of leukocyte count, fibrinogen and C-reactive protein with vascular risk factors and ischemic vascular disease. Thrombosis Research, 82, 245-255.
37. Grimm, R., Neaton, J., & Ludwig, W. (1985). Prognostic importance of the white blood cell count for coronary, cancer, and all-cause mortality. JAMA, the Journal of the American Medical Association, 254, 1932-1937.
38. Gurewich, V., Nunn, T., & Lipinski, B. (1979). Activation I of intrinsic or extrinsic blood coagulation in experimental venous thrombosis and disseminated intravascular coagulation: pathogenetic differences. Thrombosis Research, 14, 931-940.
39. Gutterridge, J. M. C., & Halliwell, B. (1990). The measurement and mechanism of lipid peroxidation in biological systems. Trends in Biochemical Sciences, 15, 129-135.
40. Haak, E. S., Usadel, K. H., Kohleisen, M., Yimaz, A., Kusterer, K., & Haak, T. (1999). The effect of alpha-lipoic acid on the neurovascular reflex arc in patients with diabetic neurophathy assessed by capillary microscopy. Microvascular Research, 58, 28-34.
41. Haffner, S. M. (2000). Coronary heart disease in patients with diabetes. New England Journal of Medicine, 342, 1040-1042.
42. Hashimoto, M., Takeda, A., Hsu, L. J., Takenouchi, T., & Masliah, E. (1999). Role of cytochrome c as a stimulator of alpha-synuclein aggregation in Lewy body disease. Journal of Biological Chemistry, 274, 28849-28852.
43. Held, C., Hjemdahl, P., Wallen, N. H., Bjorkander, I., Forslund, L., Wiman, B., & Rehnqvist, N. (2000). Inflammatory and hemostatic markers in relation to cardiovascular prognosis in patients with stable anginapectoris. Results from the APSIS study. Atherosclerosis, 148, 179-188.
44. Henschen-Edman, A. H. (1997). Photo-oxidation of histidine as a probe for aminoterminal conformational changes during fibrinogen - fibrin conversion. Cellular and Molecular Life Sciences, 53, 29-33.
45. Ho, E., & Bray, T. M. (1999). Antioxidants, NFkB activation, and diabetogenesis. Proceedings of the Society for Experimental Biology and Medicine, 222, 205-213.
46. Holvoet, P., Dock, J., Landeloos, M., Brouwers, E., Luijtens, K., Arnout, J., Lessafre, E., Vanrenterghem, Y., & Collen, D. (1996). Correlation between oxidized low density lipoproteins and von Willebrand factor in chronic renal failure. Thrombosis and Haemostasis, 76, 663-669.
47. Horie, T., Awazu, S., Itakura, Y., & Fuwa, T. (1992). Identified diallyl polysulfides from an aged garlic extract which protects the membranes from lipid peroxydation. Planta Medica, 58, 468-477.
48. Huggins, T. G., Wells-Knecht, M. C., Detories, N. A., Baynes, J. W., & Thorpe, S. R. (1993). Formation of o-tyrosine and dityrosine in protein during radilytic and metal-catalyzed oxidation. Journal of Biological Chemistry, 268, 12341-12348.
49. Ide, N., & Lau, B. H. S. (1999). Aged garlic extract attenuates intracellular oxidative stress. Phytomedicine, 6, 125-131.
50. Irish, A. (1998). Cardiovascular disease, fibrinogen and the acute phase response. Association with lipids and blood pressure in patients with chronic renal disease. Atherosclerosis, 137, 133-139.
51. Islam, K. N., O'Byrne, D., Devaraj, S., Palmer, B., Grundy, S. M., & Jialal, I. (2000). Alpha-tocopherol supplementation decerases oxidative susceptibility of LDL in renal failure patients on dialysis therapy. Atherosclerosis, 150, 217-224.
52. Kannel, W. B., Wolf, P. A., Castelli, W P., & D'Agnostino, R. B. (1987). Fibrinogen and risk of cardiovascular disease. The Framingham study. JAMA, the Journal of the American Medical Association, 258, 1183-1186.
53. Kanwar, R., & Balasubramanian, D. (1999). Structure and stability of the dityrosine-linked dimer of gammaB-crystallin. Experimental Eye Research, 68, 773-784.
54. Karpel, R., Marx, G., & Chevion, M. (1991). Free radical induced fibrinogen coagulation: modulation of neofibe formation by concentration, pH, and temperature. Israel Medical Journal, 27, 61-66.
55. Keaney, J. F., Simon, D. I., & Freedman, J. E. (1999). Vitamin E and vascular homeostasis: implications for atherosclerosis. FASEB Journal, 13, 965-975.
56. Kleinveld, H. A., Demacker, P. N., & Stalenhoef, A. F. (1994). Comparative study on the effect of low-dose vitamin E and probucol on the susceptibility of LDL to oxidation and the progression of atherosclerosis in Wanatabe heritable hyperlipidemic rabbits. Arteriosclerosis and Thrombosis, 14, 1386-1391.
57. Kostis, J. B., Turkevich, D., & Sharp, J. (1984). Association between leukocyte count and presence and extent of coronary atherosclerosis as determined by corona sry arteriography. American Journal of Cardiology, 53, 997-999.
58. Kowluru, R. A., Engerman, R. L., & Kern, T. S. (2000). Diabetes-induced metabolic abnormalities in myocardium: effect of antioxidant therapy. Free Radical Research, 32, 67-74.
59. Kuller, L. H., Velentgas, P., Barzilay, J., Beauchamp, N. J., O'Leary, D. H., & Savage, P. J. (2000). Diabetes mellitus. Subclinical cardiovascular disease and risk of incident cardiovascular disease and all-cause mortality. Arteriosclerosis, Thrombosis, and Vascular Biology, 20, 823-829.
60. Landin, K., Tengborn, L., & Smith, U. (1990). Elevated fibrinogen and PAI-1 in hypertension and related to to metabolic risk in CVD. Journal of Internal Medicine, 227, 273-278.
61. Latallo, Z. S., Budzynski, A. Z., Lipinski, B., & Kowalski, E. (1964). Inhibition of thrombin and of fibrin polymerization, two activities derived from plasmin-digested fibrinogen. Nature, 2013, 1184-1185.
62. Leeuwenburgh, C., Hardy, M. M., Hazen, S. L., Wagner, P., Oh-ishi, S., Steinbrecher, U. P., & Heinecke, J. W. (1997). Reactive nitrogen intermediates promotes LDL oxidation in human atherosclerotic intima. Journal of Biological Chemistry, 272, 1433-1436.
63. Leeuwenburgh, C., Rasmussen, J. E., Hsu, F. F., Mueller, D. M., Pennathur, S., & Heinecke, J. W. (1997). Mass spectrometric quantification of markers for protein oxidation by tyrosyl radical, copper, and hydroxyl radical in LDL isolated from human athersosclerotic plaques. Journal of Biological Chemistry, 272, 3520-3526.
64. Lefer, D. J., & Granger, N. (2000). Oxidative stress and cardiac disease. American Journal of Medicine, 109, 315-329.
65. Leinonen, J. S., Rantalaiho, V., Solakivi, T., Koivula, T., Wirta, O., Pasternack, A., Alho, H., & Lehtimaki, T. (1998). Susceptibility of LDL to oxidation is not associated with the presence of coronary heart disease or renal dysfunction in NIDDM patients. Clinica Chimica Acta, 275, 163-174.
66. Levenson, J., Giral, P., Ravazian, M., Gapieri, J., & Simon, A. (1995). Fibrinogen and silent atherosclerosis in subjects with cardiovascular risk factors. Arteriosclerosis, Thrombosis, and Vascular Biology, 15, 1269-1279.
67. Lijinen, H. R., & Collen, D. (1996). Impaired fibrinolysis and the risk for coronary heart disease. Circulation, 94, 2052-2054.
68. Lipinski, B. (1993). Effect of thiol-induced disulfide exchange in proteins on plasma clotting and fibrinolysis. Thrombosis and Haemostasis, 69, 1260.
69. Lipinski, B., Federman, S. M., & Krolewski, A. S. (1995). Plasma macromolecular protein complex: interaction with fibrin and fibrinolysis. Thrombosis Research, 78, 461-465.
70. 125I-fibrin in the generalized Shwartzman reaction and its relation to leukocytes. British Journal of Haematology, 28, 221-231.
71. Lorenz, M., Muller, M., Jablonka, B., Vigh, T., & Kirchmaier, C. M. (1998). High doses of methylene blue/light treatment crosslink the A alpha subunit of fibrinogen: influence of this photooxidation on fibrinogen binding to platelets. Haemostasis, 28, 17-24.
72. Loughrey, C. M., Young, I. S., & Lightbody, J. H. (1993). Oxidative stress in hemodialysis. Quarterly Journal of Medicine, 87, 679-683.
73. Marx, G., & Chevion, M. (1985). Fibrinogen coagulation without thrombin: reaction with vitamin C and copper(II). Thrombosis Research, 40, 11-18.
74. Maser, R. E., Wolfson, S. K., Ellis, D., Stein, E. A., Drash, A. L., Becker, D. J., Dorman, J. S., & Orchard, T. J. (1991). Cardiovascular disease and arterial calcification in IDDM: interrelations and risk factor profiles. Arteriosclerosis and Thrombosis, 11, 958-965.
75. Matteucci, E., & Giampietro, O. (2000). Oxidative sterss in families of type 1 diabetic patients. Diabetes Care, 23, 1182-1186.
76. Mechta, J., Dinerman, J., Mehta, P., Saldeen, T. G. P., Lawson, D., Donnelly, W. H., & Wallin, R. (1989). Neutrophil function in ischemic heart disease. Circulation, 79, 549-556.
77. Missov, R. M., Stolk, R. P., van der Boom, J. G., Hofman, A., Bots, M. L., Pols, H. A. P., & Grobbee, D. E. (1996). Plasma fibrinogen levels in NIDDM: the Rotterdam study. Diabetes Care, 19, 157-159.
78. Miyata, T., van Ypersele de Strihou, C., Kurokawa, K., & Baynes, J. W. (1999). Origin and significance of carbonyl stress in long-term uremic complications. Kidney International, 55, 389-399.
79. Miyazaki, H., Matsuoka, H., Itabe, H., Usui, M., Ueda, S., Okuda, S., & Imaizumi, T. (2000). Hemodialysis impairs endothelial function via oxidative stress: effects of vitamin E-coated dialyzer. Circulation, 101, 1002-1006.
80. Morel, D. W., de la Llera Moya, M., & Friday, K. E. (1994). Treatment of cholesterol-fed rabbits with dietary vitamin E and C inhibits lipoprotein oxidation but not development of atherosclerosis. Journal of Nutrition, 124, 2123-2130.
81. Munro, J. M., & Cotran, R. S. (1988). The pathogensis of atherosclerosis: atherogenesis and inflammation. Laboratory Investigation, 58, 249-261.
82. O'Brien, K. D., Alpers, C. E., Hokanson, J. E., Wang, S., & Chait, A. (1996). Oxidation-specific epitopes in human coronary atherosclerosis are not limited to oxidized LDL. Circulation, 94, 1216-1225.
83. O'Brien, R. C., Luo, M., Balazs, N., & Mercuri, J. (2000). In vitro and in vivo antioxidant properties of gliclazide. Journal of Diabetes and Its Complication, 14, 201-206.
84. Odetti, P., Garibaldi, S., Gurreri, G., Aragno, I., Dapino, D., Pronzato, M. A., & Marinari, U. M. (1996). Protein oxidation in hemodialysis and kidney transplantation. Metabolism, 45, 1319-1322.
85. Oranje, W. A., Rondas-Colbers, G.J.W.M., Swennen, G. N. M., Jansen, H., & Wolffenbuttel, B. H. R. (1999). Lack of effect on LDL oxidation and antioxidant status after improvement of metabolic control in type 2 diabetes. Diabetes Care, 22, 2083-2084.
86. Pennathrur, S., Jackson-Lewis, V., Przedborski, S., & Heinecke, J. W. (1999). Mass spectrometric quantification of 3-nitrotyrosine, ortho-tyrosine, and o,o′-dityrosine in brain tissue of 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine-treated mice, a model of oxidative stress in Parkinson's disease. Journal of Biological Chemistry, 274, 34621-34628.
87. Pyorala, K., Laakso, M., & Uusitupa, M. (1987). Diabetes and atherosclerosis: an epidemiologic view. Diabetes Metabolism Review, 3, 463-524.
88. Rao, G. H. R., & Parthasarathy, A. C. (1996). Antioxidants, atherosclerosis and thrombosis. Prostaglandins, Leukotrienes and Essential Fatty Acids, 54, 155-166.
89. Retzinger, G. S., DeAnglis, A. P., & Pattto, S. J. (1998). Adsorption of fibrinogen to droplets of liquid hydrophobic phases. Functionality of the bound protein and biological implications. Arteriosclerosis, Thrombosis, and Vascular Biology, 18, 1948-1957.
90. Ridker, P. M., Hennekens, C. H., Buring, J. E., & Rifai, N. (2000). C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. New England Journal of Medicine, 342, 836-843.
91. Rokitansky, C. (1952). Abnormal conditions of the arteries. In: A manual of pathological anatomy vol. 4 (Part II, Chapter 3, London Sydenham Society, pp. 144-152).
92. Ruhnaut, K. J., Meissnert, H. P., Finn, J. R., Reljanoic, M., Lobisch, M., Schuette, K., Nehdrich, D., Tritschler, H. J., Mehnert, H., & Ziegler, D. (1999). Effects of 3-week oral treatment with the antioxidant thioctic acid (alpha-lipoic acid) in symptomatic diaberic polyneuropathy. Diabetic Medicine, 16, 1040-1043.
93. Sagripanti, A., & Barsotti, G. (1995). Hypercoagulability, intraglomerular coagulation, and thromboembolism in nephrotic syndrome. Nephron, 70, 271-281.
94. Sakamoto, N., Shioya, T., Serizawa, T., & Akashi, M. (1999). Direct observation of fibrinogen - heparinoid complexes formation using surface plasmon resonance. Bioconjugate Chemistry, 10, 538-543.
95. Salomaa, V., Stinson, V., Kark, J. D., Folsom, A. R., Davis, C. E., & Wu, K. K. (1995). Association of fibrinolytic parameters with early atherosclerosis: the ARIC Study. Circulation, 91, 284-290.
96. Shacter, E., Williams, J. A., & Levine, R. L. (1995). Oxidative modification of fibrinogen inhibits thrombin-catalyzed clot formation. Free Radical Biology & Medicine, 18, 815-821.
97. Shimizu, A., Saito, Y., & Inada, Y. (1986). Distinctive role of histidine-16 of the B beta chain of fibrinogen in the end-to-end association of fibrin. Proceedings of the National Academy of Sciences of the United States of America, 83, 591-593.
98. Smith, E. B. (1986). Fibrinogen, fibrin and fibrin degradation products in relation to atherosclerosis. Clinical Haematology, 15, 355-370.
99. Souza, J. M., Giasson, B. I., Chen, Q., Lee, V.M.-Y., & Ischiropoulos, H. (2000). Dityrosine cross-linking promotes formation of stable alpha-synuclein polymers. Journal of Biological Chemistry, 275, 18344-18349.
100. Steinbrecher, U. P., & Lougheed, M. (1992). Scavenger receptor-independent stimulation of cholesterol estirification in lipoprotein extracted from human aortic intima. Arteriosclerosis and Thrombosis, 12, 608-625.
101. Steinbrecher, U. P., Zhang, H. F., & Lougheed, M. (1990). Role of oxidatively modified LDL in atherosclerosis. Free Radical Biology & Medicine, 9, 155-168.
102. Stevens, M. J., Obrosova, I., Cao, X., van Huysen, C., & Greene, D. A. (2000). Effects of DL-alpha-lipoic acid on peripheral nerve conduction, blood flow, energy metabolism, and oxidative stress in experimental diabetic neuropathy. Diabetes, 49, 1006-1015.
103. Stief, T. W., Kurz, J., Doss, M. O., & Fareed, J. (2000). Singlet oxygen inactivates fibrinogen, factor V, factor VIII, factor X, and platelet aggregation of human blood. Thrombosis Research, 97, 473-480.
104. Struck, M., Watkins, T., Tomeo, A., Halley, J., Birenbaum, M., & Jordan, K. L. (1994). Effect of red and white wine on serum lipids, platelet aggregation, oxidation products and antioxidants: a preliminary report. Nutrition Research, 14, 1811-1891.
105. Sutherland, W. H. F., Walker, R. J., Ball, M. J., Stapley, S. A., & Robertson, M. C. (1995). Oxidation of LDL from patients with renal failure or renal transplant. Kidney International, 48, 227-232.
106. Takemura, T., Yoshika, K., Akano, N., Miyamoto, H., Matsumoto, K., & Maki, S. (1987). Glomerular deposition of cross-linked fibrin in human kidney disease. Kidney International, 32, 102-111.
107. Upchurch, G. R., Ramdev, N., Walsh, M. T., & Loscalzo, J. (1998). Prothrombotic consequences of the oxidation of fibrinogen and their inhibition by Aspirin. Journal of Thrombosis and Thrombolysis, 5, 9-14.
108. Vaziri, N. D., Smith, D. H. G., Winer, R. L., Weber, M. A., Gonzales, E., & Neutel, J. M. (1993). Coagulation and inhibitory and fibrinolytic proteins in essential hypertension. Journal of the American Society of Nephrology, 4, 222-228.
109. Violi, F., Marino, R., Milite, M. T., & Loffredo, L. (1999). Nitric oxide and its role in lipid peroxidation. Diabetes Metab Res Rev, 15, 283-288.
110. Wells-Knecht, M. C., Huggins, T. G., Dyer, D. G., Thorpe, S. R., & Baynes, J. W (1993). Oxidized amino acids in lens proteins with age. Journal of Biological Chemistry, 268, 12348-12352.
111. West, I. C. (2000). Radicals and oxidative stress in diabetes. Diabetic Medicine, 17, 171-180.
112. Witko-Sarsat, V., Friedlander, M., Capeillere-Blandin, C., Nguyen-Khoa, A. T., Nguyen, A. T., Zingraff, J., Jungers, P., & Descamps-Latscha, B. (1996). Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney International, 49, 1304-1313.
113. Yarnell, J. W G., Baker, I. A., Sweetnam, P. M., Bainton, D., O'Brien, J. R., Wanner, C., & Eldwood, P. C. (1991). Fibrinogen, viscosity, and white blood cell count are major risk factors for ischemic heart disease. Circulation, 83, 836-844.
114. Ziegler, D., Reljanovic, M., Mehnert, H., & Gries, F. A. (1999). Alphalipoic acid in the treatment of diabetic polyneuropthy in Germany: current evidence from clinical trials. Experimental and Clinical Endocrinology & Diabetes, 107, 421-430.
115. Zimmermann, J., Herlinger, S., Pruy, A., Metzger, T., & Wanner, C. (1999). Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney International, 55, 648-658.